LIAISON XL MUREX HBeAg, LIAISON XL MUREX Control HBeAg

FDA Premarket Approval P180048

Pre-market Approval Supplement Details

The liaison® xl murex hbeag assay is an in vitro chemiluminescent immunoassay (clia) for the qualitative detection of hepatitis b virus (hbv) e antigen (hbeag) in human adult and pediatric (2-21 years) serum and plasma (lithium and sodium heparin, sodium citrate and k2 edta), including separator tubes, on the liaison® xl analyzer. Assay results in conjunction with other laboratory results and clinical information may be used as an aid in the diagnosis of hepatitis b virus (hbv) infection in patients with symptoms of hepatitis or who may be at risk for hepatitis b (hbv) infection. The assay is not intended for use in screening blood, plasma, or tissue donors. The liaison® xl murex control hbeag (negative and positive) is intended for use as assayed quality control samples to monitor the performance of the liaison® xl murex hbeag assay. The performance characteristics of liaison® xl murex control hbeag have not been established for any other assays or instrument platforms.

DeviceLIAISON XL MUREX HBeAg, LIAISON XL MUREX Control HBeAg
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantDiaSorin Inc.
Date Received2018-12-14
Decision Date2020-08-29
PMAP180048
SupplementS
Product CodeLOM 
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address DiaSorin Inc. 1951 Northwestern Avenue stillwater, MN 55082

Supplemental Filings

A PHP Error was encountered

Severity: Notice

Message: Undefined offset: 0

Filename: fda.report/pma_item.php

Line Number: 132

Backtrace:

File: /var/www/fda.report/pma_item.php
Line: 132
Function: _error_handler

Supplement NumberDateSupplement Type
P180048Original Filing

© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.